Northern Trust Corp Trims Position in Teleflex Incorporated $TFX

Northern Trust Corp lessened its stake in Teleflex Incorporated (NYSE:TFX) by 34.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,665 shares of the medical technology company’s stock after selling 158,181 shares during the period. Northern Trust Corp owned 0.69% of Teleflex worth $42,102,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its stake in Teleflex by 69.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company’s stock worth $119,927,000 after buying an additional 355,720 shares during the period. Diamond Hill Capital Management Inc. increased its stake in Teleflex by 122.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company’s stock worth $80,784,000 after buying an additional 322,222 shares during the period. TD Asset Management Inc increased its stake in Teleflex by 0.7% in the 1st quarter. TD Asset Management Inc now owns 490,000 shares of the medical technology company’s stock worth $67,713,000 after buying an additional 3,310 shares during the period. Deutsche Bank AG grew its holdings in Teleflex by 62.5% during the 4th quarter. Deutsche Bank AG now owns 407,129 shares of the medical technology company’s stock worth $72,461,000 after acquiring an additional 156,524 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Teleflex by 12.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 373,388 shares of the medical technology company’s stock worth $66,456,000 after acquiring an additional 40,128 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analyst Upgrades and Downgrades

TFX has been the topic of several recent research reports. Truist Financial dropped their target price on shares of Teleflex from $140.00 to $137.00 and set a “hold” rating on the stock in a report on Monday, May 5th. Wells Fargo & Company dropped their target price on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Mizuho increased their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a report on Friday, August 1st. Wall Street Zen upgraded shares of Teleflex from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Finally, Morgan Stanley dropped their target price on shares of Teleflex from $191.00 to $173.00 and set an “overweight” rating on the stock in a report on Monday, May 5th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Teleflex currently has an average rating of “Hold” and a consensus price target of $141.57.

Teleflex Stock Down 2.5%

NYSE:TFX opened at $126.28 on Friday. Teleflex Incorporated has a fifty-two week low of $108.90 and a fifty-two week high of $249.90. The stock has a market capitalization of $5.58 billion, a P/E ratio of 29.71, a P/E/G ratio of 1.81 and a beta of 1.08. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41. The company’s 50-day simple moving average is $118.88 and its 200-day simple moving average is $129.69.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business had revenue of $780.90 million for the quarter, compared to analysts’ expectations of $771.53 million. During the same period last year, the business earned $3.42 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, equities analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Stockholders of record on Friday, August 15th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, August 15th. Teleflex’s dividend payout ratio (DPR) is currently 32.00%.

Insiders Place Their Bets

In related news, CEO Liam Kelly bought 1,500 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average cost of $115.07 per share, for a total transaction of $172,605.00. Following the purchase, the chief executive officer directly owned 45,267 shares of the company’s stock, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gretchen R. Haggerty bought 500 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was bought at an average price of $114.75 per share, with a total value of $57,375.00. Following the completion of the purchase, the director directly owned 6,305 shares in the company, valued at $723,498.75. This represents a 8.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 5,500 shares of company stock worth $633,590. Insiders own 1.40% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.